Literature DB >> 24569928

OK-432 sclerotherapy of lymphatic malformation in the head and neck: factors related to outcome.

Dong Wook Kim1.   

Abstract

BACKGROUND: No previous study to the best of our knowledge has examined the multiple factors related to the outcome of OK-432 sclerotherapy of lymphatic malformations.
OBJECTIVE: This study aimed to assess factors related to the successful outcome of OK-432 sclerotherapy for lymphatic malformations in the head and neck region.
MATERIALS AND METHODS: During a 6-year period, OK-432 sclerotherapy was performed in 26 patients with lymphatic malformations. Several factors related to the efficacy of OK-432 sclerotherapy were evaluated, including the type (macrocystic or microcystic), the maximum lesion diameter, amount and hemorrhagic cytology of the aspirate, degree of aspiration, injected dose of OK-432 and post-therapy inflammation-related symptom. In all cases, ultrasound (US) follow-up was performed.
RESULTS: Of the 26 cases, 13 (50%) showed successful elimination of the lymphatic malformations in the follow-up US after the initial session, and all successful cases were of the macrocystic type. The type of lymphatic malformation and the success of OK-432 sclerotherapy were significantly related (P = 0.0149). Of the 16 cases of complete aspiration, 11 (68.8%) showed a successful outcome. Further, of the 17 cases with inflammation-related symptom, 13 (76.5%) showed a successful outcome. While the degree of aspiration and presence of inflammation-related symptom showed a significant relationship with the success of OK-432 sclerotherapy (P < 0.05), no other factors showed a significant relationship.
CONCLUSION: The study results suggest that the macrocystic type and complete aspiration of cystic contents were important factors for the success of OK-432 sclerotherapy of lymphatic malformations, and that inflammation-related symptom was a predictor of a successful outcome.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24569928     DOI: 10.1007/s00247-014-2889-0

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  23 in total

1.  Treatment of cystic hygroma by intralesional bleomycin injection: experience in 70 patients.

Authors:  R Niramis; S Watanatittan; T Rattanasuwan
Journal:  Eur J Pediatr Surg       Date:  2010-02-22       Impact factor: 2.191

2.  Treatment of lymphangioma in children: our experience of 128 cases.

Authors:  Tadaharu Okazaki; Saori Iwatani; Toshihiro Yanai; Hiroyuki Kobayashi; Yoshifumi Kato; Takashi Marusasa; Geoffrey J Lane; Atsuyuki Yamataka
Journal:  J Pediatr Surg       Date:  2007-02       Impact factor: 2.545

3.  Lymphatic malformations of the head and neck: a retrospective review and a support for staging.

Authors:  M Hamoir; I Plouin-Gaudon; P Rombaux; G Francois; A S Cornu; G Desuter; P Clapuyt; C Debauche; G Verellen; C Beguin
Journal:  Head Neck       Date:  2001-04       Impact factor: 3.147

4.  Treatment of lymphangiomas of the head and neck in children by intralesional injection of OK-432 (Picibanil).

Authors:  C Brewis; J P Pracy; D M Albert
Journal:  Clin Otolaryngol Allied Sci       Date:  2000-04

5.  Dynamic Toll-like receptor expression predicts outcome of sclerotherapy for lymphatic malformations with OK-432 in children.

Authors:  Marc Reismann; Nader Ghaffarpour; Ethel Luvall; Adan C Jirmo; Ola Winqvist; Josephine Radtke; Tomas Wester; Gösta Claesson
Journal:  J Surg Res       Date:  2013-10-02       Impact factor: 2.192

6.  Guidelines for the successful treatment of lymphangioma with OK-432.

Authors:  B Banieghbal; M R Q Davies
Journal:  Eur J Pediatr Surg       Date:  2003-04       Impact factor: 2.191

Review 7.  Percutaneous sclerotherapy of lymphatic malformations with doxycycline.

Authors:  Patricia E Burrows; Ragheed K Mitri; Ahmad Alomari; Horacio M Padua; David J Lord; Mary Beth Sylvia; Steven J Fishman; John B Mulliken
Journal:  Lymphat Res Biol       Date:  2008       Impact factor: 2.589

8.  Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial.

Authors:  Chantal M Giguère; Nancy M Bauman; Yutaka Sato; Diane K Burke; John H Greinwald; Seth Pransky; Peggy Kelley; Keith Georgeson; Richard J H Smith
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2002-10

9.  Effect of picibanil (OK432) on neutrophil-mediated antitumor activity: implication of monocyte-derived neutrophil-activating factors.

Authors:  K D Yang; R M Stone; C S Lee; T Y Chao; S N Cheng; M F Shaio
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

10.  OK-432 sclerotherapy in head and neck lymphangiomas: long-term follow-up result.

Authors:  Jae Chul Yoo; Youngjin Ahn; Yune Syung Lim; J Hun Hah; Tack-Kyun Kwon; Myung-Whun Sung; Kwang Hyun Kim
Journal:  Otolaryngol Head Neck Surg       Date:  2009-01       Impact factor: 3.497

View more
  5 in total

1.  A nomogram for predicting sclerotherapy response for treatment of lymphatic malformations in children.

Authors:  Zhiping Wu; Yun Zou; Ronghua Fu; Pingliang Jin; Hua Yuan
Journal:  Eur J Med Res       Date:  2022-10-21       Impact factor: 4.981

2.  Japanese clinical practice guidelines for vascular anomalies 2017.

Authors:  Hidefumi Mimura; Sadanori Akita; Akihiro Fujino; Masatoshi Jinnin; Mine Ozaki; Keigo Osuga; Hiroki Nakaoka; Eiichi Morii; Akira Kuramochi; Yoko Aoki; Yasunori Arai; Noriko Aramaki; Masanori Inoue; Yuki Iwashina; Tadashi Iwanaka; Shigeru Ueno; Akihiro Umezawa; Michio Ozeki; Junko Ochi; Yoshiaki Kinoshita; Masakazu Kurita; Shien Seike; Nobuyuki Takakura; Masataka Takahashi; Takao Tachibana; Kumiko Chuman; Shuji Nagata; Mitsunaga Narushima; Yasunari Niimi; Shunsuke Nosaka; Taiki Nozaki; Kazuki Hashimoto; Ayato Hayashi; Satoshi Hirakawa; Atsuko Fujikawa; Yumiko Hori; Kentaro Matsuoka; Hideki Mori; Yuki Yamamoto; Shunsuke Yuzuriha; Naoaki Rikihisa; Shoji Watanabe; Shinichi Watanabe; Tatsuo Kuroda; Shunsuke Sugawara; Kosuke Ishikawa; Satoru Sasaki
Journal:  Jpn J Radiol       Date:  2020-04       Impact factor: 2.374

3.  Japanese Clinical Practice Guidelines for Vascular Anomalies 2017.

Authors:  Hidefumi Mimura; Sadanori Akita; Akihiro Fujino; Masatoshi Jinnin; Mine Ozaki; Keigo Osuga; Hiroki Nakaoka; Eiichi Morii; Akira Kuramochi; Yoko Aoki; Yasunori Arai; Noriko Aramaki; Masanori Inoue; Yuki Iwashina; Tadashi Iwanaka; Shigeru Ueno; Akihiro Umezawa; Michio Ozeki; Junko Ochi; Yoshiaki Kinoshita; Masakazu Kurita; Shien Seike; Nobuyuki Takakura; Masataka Takahashi; Takao Tachibana; Kumiko Chuman; Shuji Nagata; Mitsunaga Narushima; Yasunari Niimi; Shunsuke Nosaka; Taiki Nozaki; Kazuki Hashimoto; Ayato Hayashi; Satoshi Hirakawa; Atsuko Fujikawa; Yumiko Hori; Kentaro Matsuoka; Hideki Mori; Yuki Yamamoto; Shunsuke Yuzuriha; Naoaki Rikihisa; Shoji Watanabe; Shinichi Watanabe; Tatsuo Kuroda; Shunsuke Sugawara; Kosuke Ishikawa; Satoru Sasaki
Journal:  J Dermatol       Date:  2020-03-22       Impact factor: 4.005

4.  Cervical cystic hygroma in an adult.

Authors:  Serhan Derin; Murat Şahan; Yelda Dere; Neşat Çullu; Leyla Şahan
Journal:  Case Rep Pathol       Date:  2014-12-07

5.  Microbubbles in macrocysts - Contrast-enhanced ultrasound assisted sclerosant therapy of a congenital macrocystic lymphangioma: a case report.

Authors:  Carlos Menendez-Castro; Maren Zapke; Fabian Fahlbusch; Heiko von Goessel; Wolfgang Rascher; Jörg Jüngert
Journal:  BMC Med Imaging       Date:  2017-07-06       Impact factor: 1.930

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.